CEO Stephen Whitehead leaves ABPI
October 1, 2015Medical Communications ABPI, Alison Clough, Stephen Whitehead
The ABPI has confirmed that CEO Stephen Whitehead has left the organisation. Speaking on behalf of the Board, John Kearney, …
Dr Karen Bernstein joins Ovid and Vitae boards
October 1, 2015Medical Communications, Sales and Marketing Dr Karen Bernstein, Ovid Therapeutics, Vitae Pharmaceuticals
Ovid Therapeutics has announced the appointment of Karen Bernstein to the company’s Board of Directors. Dr Bernstein says: “I have …
Verona Pharma’s respiratory drug proves positive in study
October 1, 2015Research and Development COPD, verona pharma
Verona Pharma has announced encouraging positive headline data of the third and final part of a randomised, clinical study in …
Quick test minimises unnecessary antibiotic prescribing
October 1, 2015Medical Communications antibiotic resistance
New data presented at this week’s Royal College of General Practitioners (RCGP) Annual Conference reveals that in real-world general practice, …
Novartis’s secukinumab meets Phase 3 goals
October 1, 2015Research and Development Novartis, Secukinumab, arthritis
Novartis has announced that its secukinumab medication for treatment of psoriatic arthritis (PsA), met its primary endpoint in the pivotal …
Pfizer’s self-injectable contraceptive becomes UK’s first
September 30, 2015Medical Communications, Research and Development, Sales and Marketing Pfizer, Syayana Press
Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate), is now available to women in the UK for administration by self-injection following …
Study shows Novartis’s Afinitor positively reduces tumors
September 30, 2015Research and Development Afinitor, Novartis
Novartis has announced the results of a Phase III pivotal study, showing Afinitor (everolimus) tablets reduced the risk of progression …
Genentech’s ocrelizumab shows efficacy in phase III trial
September 30, 2015Research and Development Genentech, MS, Roche, ocrelizumab
Roche subsidiary Genentech has announced positive results from a pivotal phase III study of its investigational medicine ocrelizumab in people …
Heptares awarded $5.5 million grant to combat cocaine addiction
September 30, 2015Research and Development Heptares
Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, has been awarded a grant from the National Institute …
Roche says Esbriet shown to extend lives of IPF patients
September 30, 2015Medical Communications, Research and Development, Sales and Marketing Esbriet, Roche, idiopathic pulmonary fibrosis
Roche has presented new clinical data and abstracts on Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF), showing …
Featured market report: US pharmaceutical market to 2018
September 29, 2015Manufacturing and Production, Sales and Marketing market reports
This report forecasts US pharmaceutical (prescription and over-the-counter) shipments and demand at the manufacturers’ level, to 2018.This industry forecast report …
New study reveals true impact of severe asthma in Europe
September 29, 2015Research and Development ERS2015, asthma
The results of a new, comprehensive survey have revealed the true burden of severe asthma faced by patients across Europe. …
It’s finally here: 3D-printed pills and technology in pharma
September 29, 2015Manufacturing and Production 3-D printing, 3d printing, Aprecia, Spritam, manufacturing, production
The notion of tailor-made drugs, which are customised to an individual patient’s needs, has seen remarkable progress of late. This …
Georges Gemayel appointed non-executive chairman of Enterome
September 29, 2015Manufacturing and Production
Drug and diagnostics development firm Enterome Bioscience SA has appointed Dr Georges Gemayel to the Enterome board as a non-executive …
UN calls on pharma industry to make medicines more affordable
September 29, 2015Manufacturing and Production AIDS, HIV, Michel Sidibe, UNAIDS, United Nations, antiretroviral treatments
The United Nations AIDS agency, UNAIDS, has called on governments and the pharmaceutical industry to ensure that medicines remain accessible …
FDA withdraws approval for Sun Pharma’s epilepsy drug
September 29, 2015Manufacturing and Production Elepsia, FDA, Sun Pharma, epilepsy, levetiracetam, manufacturing, productions, seizures
Manufacturing problems at Sun Pharma’s production site has led the FDA to revoke the company’s approval for Elepsia XR for …
Bristol-Myers Squibb notches kidney cancer first with Opdivo
September 28, 2015Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma
Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …
Alexion to challenge Canadian price of Soliris in court
September 28, 2015Sales and Marketing Alexion, Canada, Drug pricing, Patented Medicine Prices Review Board, eculizumab, soliris
Alexion Pharmaceuticals is taking the Canadian government to court for its attempt to lower the price of the rare disease …
Sanofi and Regeneron given European nod for Praluent
September 28, 2015Sales and Marketing European Commission, Regeneron, Sanofi, alirocumab, high cholesterol, marketing authorisation, praluent
The European Commission (EC) has approved the marketing authorisation of Sanofi and Regeneron’s cholesterol drug Praluent. The heart drug is …
FDA approves Novo Nordisk’s diabetes drugs
September 28, 2015Sales and Marketing FDA, Novo Nordisk, Ryzodeg, Tresiba, diabetes, insulin
The FDA has approved two Novo Nordisk drugs, Tresiba and Ryzodeg, for the treatment of type 2 diabetes in adults.The …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
